Sanofi: upcoming dates

Recent

• Business10/04/2026@HealthDesk

  Sanofi and Regeneron Expand Their Alliance With US$1 Billion Upfront

  46-48 Avenue de la Grande Armée, Paris, FranceSanofi

  

  Starts 10/01/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins86% CONFIDENCEOverall confidence: 86%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better4 days agoSanofi's^[1] press release is datelined "Paris and Tarrytown, NY, October 1, 2026" and the same release was furnished to the SEC^[3].

  On 1 October 2026 Sanofi and Regeneron announced they will co-develop four new long-acting immunology antibodies; Regeneron receives US$1 billion upfront and up to US$7 billion more in milestones.

  $1B

  00
• Business10/04/2026@EconDesk

  Sanofi Q2 2026: Sales Up 17.8%, Dupixent Tops EUR 5 Billion, Guidance Raised

  46-48 Avenue de la Grande Armée, Paris, FranceSanofi

  

  Starts 07/30/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better67 days agoSanofi's^[1] results release is dated July 30, 2026, as is the Pharmaletter^[3] report of the guidance upgrade.

  On 30 July 2026 Sanofi reported second-quarter sales up 17.8% at constant rates to EUR 11.6 billion and business EPS of EUR 2.09, and raised its 2026 outlook to about 10% sales growth.

  00
• Health10/04/2026@HealthDesk

  Sanofi Drops Amlitelimab in Atopic Dermatitis

  46-48 Avenue de la Grande Armée, Paris, FranceSanofi

  

  Starts 07/24/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins85% CONFIDENCEOverall confidence: 85%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better73 days agoSanofi's^[1] press release is datelined "Paris, July 24, 2026" and HCPLive^[3] and BioSpace^[4] carried it the same day.

  On 24 July 2026 Sanofi announced it was discontinuing development of its OX40-ligand antibody amlitelimab in moderate-to-severe atopic dermatitis and would not file it with regulators.

  00
• Health10/04/2026@HealthDesk

  EU Approves Sanofi's Cenrifki, a First Disability-Targeting SPMS Drug

  46-48 Avenue de la Grande Armée, Paris, FranceSanofi

  

  Starts 06/23/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins86% CONFIDENCEOverall confidence: 86%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better104 days agoSanofi's^[1] press release is datelined "Paris, June 23, 2026" and PharmaTimes^[4]' report of the approval is dated 23 June 2026.

  On 23 June 2026 the European Commission approved Sanofi's Cenrifki (tolebrutinib) for secondary progressive multiple sclerosis without relapses, the first EU medicine aimed at disability progression in that group.

  00
• Business10/04/2026@EconDesk

  Sanofi Replaces CEO Paul Hudson With Merck KGaA's Belén Garijo

  46-48 Avenue de la Grande Armée, Paris, FranceSanofi

  

  Starts 02/12/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better235 days agoSanofi's^[1] press release is dated "Paris, February 12, 2026" and says the board met on 11 February; pharmaphorum^[3] and Pharmaceutical Technology^[4] both report it on 12 February.

  On 12 February 2026 Sanofi's board said it would not renew Paul Hudson, whose last day as CEO was 17 February, and named Merck KGaA chief Belén Garijo to succeed him after the 29 April shareholder meeting.

  00
• Business10/04/2026@HealthDesk

  Sanofi Completes Its US$2.2 Billion Purchase of Dynavax

  46-48 Avenue de la Grande Armée, Paris, FranceSanofi

  

  Starts 02/10/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins86% CONFIDENCEOverall confidence: 86%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better237 days agoSanofi's^[1] press release is dated February 10, 2026 and says it accepted tendered shares for payment and completed the merger that day, after the tender offer expired on 9 February.

  On 10 February 2026 Sanofi completed the acquisition of vaccine maker Dynavax at US$15.50 a share in cash, adding the two-dose hepatitis B vaccine Heplisav-B and a shingles vaccine candidate.

  $2.2B

  00